一项比较Linvoseltamab与Daratumumab治疗高危冒烟型多发性骨髓瘤(HR-SMM)的研究 (LINKER-SMM2)
一项针对具有进展为多发性骨髓瘤高风险的冒烟型多发性骨髓瘤参与者的林沃塞单抗对比达雷妥尤单抗的3期、随机、开放标签研究
This study is researching an experimental drug called linvoseltamab (also called "study drug") compared to another drug called daratumumab, in participants with Smoldering Multiple Myeloma (SMM), who are at a High Risk (HR) of developing active multiple myeloma.
The aim of this study is to find out whether linvoseltamab is better than daratumumab in delaying the development of MM.
The study is looking at several other research questions, including:
- What side effects may happen from taking the study drug
- How much study drug is in the blood at different times
- Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)
研究概览
研究类型
注册 (估计的)
阶段
- 第三阶段
联系人和位置
学习联系方式
- 姓名:Clinical Trials Administrator
- 电话号码:844-734-6643
- 邮箱:clinicaltrials@regeneron.com
学习地点
-
-
-
Matsumoto-shi、日本、399-8701
- 招聘中
- National Hospital Organization Matsumoto Medical Center
-
-
Aichi-ken
-
Nagoya、Aichi-ken、日本、467-8602
- 招聘中
- Nagoya City University Hospital
-
-
Okayama-ken
-
Okayama、Okayama-ken、日本、701-1192
- 招聘中
- National Hospital Organization Okayama Medical Center
-
-
Tokushima
-
Tokushima、Tokushima、日本、770-8539
- 招聘中
- Tokushima Prefectural Central Hospital
-
-
Yamanashi
-
Kofu、Yamanashi、日本、400-8506
- 招聘中
- Yamanashi Prefectural Central Hospital
-
-
-
-
Cannes
-
Cannes、Cannes、法国、06414
- 招聘中
- Centre Hospitalier de Cannes
-
-
Gironde
-
Pessac、Gironde、法国、33600
- 招聘中
- Service d'Hematologie
-
-
Nord
-
Lille、Nord、法国、59020
- 招聘中
- Hopital Saint Vincent de Paul
-
-
Occitanie
-
Toulouse、Occitanie、法国、31059
- 招聘中
- Centre Hospitalier Universitaire (CHU) de Toulouse
-
-
-
-
-
Katowice、波兰、40-519
- 招聘中
- Pratia Onkologia Katowice
-
-
Wielkopolska
-
Skorzewo、Wielkopolska、波兰、60185
- 招聘中
- Aidport Sp. z o.o.
-
-
-
-
Arizona
-
Phoenix、Arizona、美国、85054
- 招聘中
- Mayo Clinic Phoenix, Mayo Clinic Building
-
-
Georgia
-
Atlanta、Georgia、美国、30322
- 招聘中
- Emory University - Winship Cancer Institute
-
-
Massachusetts
-
Boston、Massachusetts、美国、02215
- 招聘中
- Dana Farber / Harvard Cancer Center
-
-
Michigan
-
Detroit、Michigan、美国、48201
- 招聘中
- Barbara Ann Karmanos Cancer Institute - Detroit
-
-
Minnesota
-
Rochester、Minnesota、美国、55905
- 招聘中
- Mayo Clinic
-
-
Missouri
-
St Louis、Missouri、美国、63110
- 招聘中
- Washington University School of Medicine in St. Louis
-
-
New York
-
New York、New York、美国、10032
- 招聘中
- Columbia University Medical Center
-
New York、New York、美国、10021
- 招聘中
- Memorial Sloan Kettering Cancer Center
-
-
Ohio
-
Columbus、Ohio、美国、43210
- 招聘中
- Ohio State University
-
-
-
-
-
Leicester、英国、LE1 5WW
- 招聘中
- University Hospitals Leicester
-
London、英国、W12 0HS
- 招聘中
- Hammersmith Hospital, Imperial College Healthcare NHS Trust
-
London、英国、EC1A 7BE
- 招聘中
- Saint Bartholomew's Hospital
-
-
Cornwall
-
Truro、Cornwall、英国、TR1 3LJ
- 招聘中
- Royal Cornwall Hospital
-
-
Norfolk
-
Norwich、Norfolk、英国、NR4 7UY
- 招聘中
- Norfolk and Norwich University Hospital
-
-
Surrey
-
Sutton、Surrey、英国、SM2 5PT
- 招聘中
- The Royal Marsden NHS Foundation Trust
-
-
-
-
-
Seoul、韩国、05505
- 招聘中
- Asan Medical Center
-
Seoul、韩国、03080
- 招聘中
- Seoul National University Hospital
-
Seoul、韩国、03722
- 招聘中
- Severance Hospital, Yonsei University Health System
-
Seoul、韩国、06351
- 招聘中
- Samsung Medical Center
-
Seoul、韩国、06591
- 招聘中
- Seoul St. Mary's Hospital, The Catholic University of Korea
-
-
Gyeonggi-do
-
Suwon、Gyeonggi-do、韩国、16247
- 招聘中
- The Catholic University of Korea, St Vincents Hospital
-
-
Jeollanam-do
-
Hwasun、Jeollanam-do、韩国、58128
- 招聘中
- Chonnam National University Hwasun Hospital
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Key Inclusion Criteria:
- Eastern Cooperative Oncology Group performance status score ≤1
- SMM diagnosis per IMWG criteria as defined in the protocol
- Meets HR-SMM criteria by 1 of the risk models as defined in the protocol
Key Exclusion Criteria:
- Evidence of myeloma-defining events attributable to the underlying plasma cell dyscrasia, as defined in the protocol
- Diagnosis of systemic light chain amyloidosis, Waldenström macroglobulinemia (lymphoplasmacytic lymphoma), plasma cell leukemia, or soft tissue plasmacytoma
- History of neurodegenerative condition, progressive multifocal leukoencephalopathy, or Central Nervous System (CNS) movement disorder
- History of a seizure within the 12 months of randomization
- Prior exposure to any approved or investigational treatments directed against a clonal plasma cell disorder (including but not limited to conventional chemotherapies, radiotherapy, immunomodulatory drugs, proteasome inhibitors, anti-CD38 antibodies). Ongoing treatment with other monoclonal antibodies (eg, infliximab, rituximab) or other treatments likely to interfere with study procedures or results, as described in the protocol.
NOTE: Other protocol defined inclusion/exclusion criteria apply
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:林沃塞坦单抗
|
Administered per the protocol
其他名称:
|
|
有源比较器:达雷妥尤单抗
|
Administered per the protocol
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
根据国际骨髓瘤工作组(IMWG)标准评估的临床无进展生存期(PFS)
大体时间:最长5年
|
最长5年
|
|
根据IMWG标准的生化无进展生存期
大体时间:最长5年
|
最长5年
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
TEAE 的严重程度
大体时间:最长 3 年
|
最长 3 年
|
|
|
死亡时间
大体时间:长达9年
|
长达9年
|
|
|
根据IMWG标准的缓解持续时间(DOR)
大体时间:长达5年
|
长达5年
|
|
|
FACIT-项目GP5评分相对于基线的变化
大体时间:最长 5 年
|
最长 5 年
|
|
|
根据IMWG标准,在10^-5水平达到微小残留病(MRD)完全缓解(CR)
大体时间:长达3年
|
长达3年
|
|
|
根据IMWG标准的最佳总体缓解(BOR)
大体时间:最长3年
|
最长3年
|
|
|
实现微小残留病灶阴性
大体时间:最长3年
|
最长3年
|
|
|
持续MRD阴性
大体时间:最多3年
|
最多3年
|
|
|
MRD阴性完全缓解持续时间
大体时间:最长3年
|
最长3年
|
|
|
治疗期间出现的不良事件(TEAEs)的发生率
大体时间:最长3年
|
最长3年
|
|
|
严重不良事件(SAEs)的发生率
大体时间:最长3年
|
最长3年
|
|
|
EORTC QLQ-C30 躯体功能量表评分相对于基线的变化
大体时间:长达5年
|
长达5年
|
|
|
EORTC QLQ-C30 角色功能量表评分相对于基线的变化
大体时间:最多 5 年
|
最多 5 年
|
|
|
EORTC QLQ-C30情绪功能量表评分相对于基线的变化
大体时间:最长5年
|
最长5年
|
|
|
EORTC QLQ-C30 疲劳量表评分相对于基线的变化
大体时间:最多5年
|
最多5年
|
|
|
血清中linvoseltamab的浓度
大体时间:最长5年
|
最长5年
|
|
|
血清中linvoseltamab抗药物抗体(ADAs)的发生情况
大体时间:长达5年
|
长达5年
|
|
|
血清中linvoseltamab的ADA效价
大体时间:最长5年
|
最长5年
|
|
|
Overall Response Rate (ORR) of Partial Response or better (≥PR) per IMWG criteria
大体时间:Up to 3 years
|
Up to 3 years
|
|
|
Change from baseline score in European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire 30 (EORTC QLQ-C30) Global Health Status (GHS)/Quality of Life (QoL) scale
大体时间:Up to 5 years
|
The EORTC QLQ-C30 is a 30-item validated questionnaire developed to measure patient-reported QoL using 1 GHS/QoL scale, 5 functioning scales (physical, role, emotional, cognitive and social) and 9 symptom scales / items (fatigue, nausea/vomiting, pain, dyspnea, insomnia, appetite loss, constipation, diarrhea and financial difficulties) among patients with cancer. For the functioning scales and global health status / QoL, scores range from 1 = "very poor" to 5 = "excellent" with higher scores indicating better functioning and positive changes from baseline indicate improvement. |
Up to 5 years
|
|
Change from baseline score in EORTC QLQ-C30 pain scale
大体时间:Up to 5 years
|
The EORTC QLQ-C30 is a 30-item validated questionnaire developed to measure patient-reported QoL using 1 GHS/QoL scale, 5 functioning scales (physical, role, emotional, cognitive and social) and 9 symptom scales / items (fatigue, nausea/vomiting, pain, dyspnea, insomnia, appetite loss, constipation, diarrhea and financial difficulties) among patients with cancer. For the 9 symptom scales, scores range from 1 = "not at all" to 9 = "very much" higher scores indicate higher symptom burden and negative changes from baseline indicate improvement. |
Up to 5 years
|
|
Change from baseline score in EORTC IL478 future perspectives scale
大体时间:Up to 5 years
|
EORTC IL478 corresponds to the EORTC QLQ-Multiple Myeloma Module 20 (MY20) future Perspective Scale. This is a is a self-administered instrument to assess QoL in persons with MM. For the future perspective 3 items are analyzed. A high score for an item represents a high level of symptomatic problem. |
Up to 5 years
|
|
Change from baseline score in EuroQoL-5 Dimensions 5-Level Questionnaire Visual Analogue Scale (EQ-5D-5L VAS )
大体时间:Up to 5 years
|
The EQ-5D-5L consists of the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS). The EQ-5D-5L descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: "no problems", "slight problems", "moderate problems", "severe problems" and "extreme problems". The EQ VAS records the participant's self-rated health on a vertical visual analogue scale where the endpoints are labeled "Best imaginable health state" and "Worst imaginable health state". |
Up to 5 years
|
|
Functional Assessment of Cancer Therapy (FACIT)- Item Global Population 5 (GP5) responses
大体时间:Up to 5 years
|
FACIT-Item GP5 will be used to assess the patient-reported impact of treatment toxicity that uses a single item "I am bothered by side effects of treatment" on a 5-point scale (0 = not at all, 1 = a little bit, 2 = somewhat, 3 = quite a bit, 4 = very much). |
Up to 5 years
|
合作者和调查者
调查人员
- 研究主任:Clinical Trial Management、Regeneron Pharmaceuticals
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- R5458-HM-24145
- 2025-523252-31-00 (克蒂斯)
- 2025 (美国 NIH 拨款/合同)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing.
IPD 共享时间框架
When Regeneron has:
- received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development
- made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry)
- the legal authority to share the data, and
- ensured the ability to protect participant privacy
IPD 共享访问标准
Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf
IPD 共享支持信息类型
- 研究方案
- 树液
- 国际碳纤维联合会
- 分析代码
- 企业社会责任
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.